Loxo Oncology, Inc. – Neurotrophic Tyrosine Kinase, Receptor-related Proteins

Access Program Information

Larotrectinib (LOXO-101) expanded access is for patients with cancer with a NTRK1, NTRK2, or
NTRK3 gene fusion who are ineligible for an ongoing larotrectinib (LOXO-101) clinical trial
or have other considerations that prevent access to larotrectinib (LOXO-101) through an
existing clinical trial. Expanded access is intended to treat individual patients with
different types of cancers with a NTRK gene fusion.

Rare Disease: